StockNews.com Initiates Coverage on Cara Therapeutics (NASDAQ:CARA)

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ CARA opened at $0.34 on Wednesday. The company has a market cap of $18.70 million, a P/E ratio of -0.17 and a beta of 0.68. The stock has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.40. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.31.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The business had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. On average, analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Trading of Cara Therapeutics

An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN raised its stake in Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,935,718 shares of the biopharmaceutical company’s stock after purchasing an additional 120,660 shares during the period. Disciplined Growth Investors Inc. MN owned about 3.54% of Cara Therapeutics worth $499,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.